Immune-mediated scleritis is a painful inflammation of the white outer wall of the eye. The early symptoms of immune-mediated scleritis often include deep eye pain, redness, tearing, and pain that can spread to the face or head. It can affect adults of different ages, and it is more common in people living with an autoimmune condition. Not everyone will have the same experience. Symptoms may last for weeks or come back over time, and treatment usually involves prescription anti-inflammatory medicines and care for the underlying immune disease to help prevent vision loss.
How many people live with Immune-mediated scleritis?
A commonly cited prevalence for scleritis overall, a rare form of deep eye inflammation, is about 5.2 people per 100,000, which works out to roughly 420,000 people worldwide and about 17,000 to 18,000 people in the United States (StatPearls, 2024; United Nations, 2024; U.S. Census Bureau, 2024). Because only about 5% to 10% of scleritis is caused by infection, an estimated 90% to 95% is the immune-system-driven type, so roughly 380,000 to 400,000 people worldwide and about 16,000 to 17,000 people in the United States may be living with immune-mediated scleritis; these are estimates, not direct counts (Cleveland Clinic Journal of Medicine, 2019; StatPearls, 2024).
Overview
Immune-mediated scleritisSymptoms
Immune-mediated scleritis often causes deep, boring eye pain, marked redness, and light sensitivity. Many people with immune-mediated scleritis also notice tearing, blurred vision, and pain that can spread to the face or worsen with eye movement.
Outlook and prognosis
With prompt treatment, many people with immune-mediated scleritis keep good vision and have long quiet periods. Outlook depends on how quickly inflammation is controlled, whether both eyes are affected, and whether an autoimmune condition is also driving flare-ups.
Causes and risk factors
Immune-mediated scleritis often happens when the immune system becomes overactive, especially in people with autoimmune diseases such as rheumatoid arthritis or lupus. Risk is higher with vasculitis. Smoking may worsen inflammation.
Genetic influences
Genetics can influence who is more likely to develop immune-mediated scleritis, but they are only part of the picture. Immune-related gene variations may raise risk, while infections, autoimmune disease, and other triggers also matter.
Diagnosis
Immune-mediated scleritis is diagnosed through an eye exam, your symptoms, and tests to rule out infection or injury. Doctors may use slit-lamp exam, blood tests, and sometimes imaging. Early diagnosis of immune-mediated scleritis helps protect vision.
Treatment and drugs
Treatment for immune-mediated scleritis usually starts with medicines that calm inflammation, often steroid eye drops, anti-inflammatory tablets, or steroids. If it keeps coming back or is severe, many living with immune-mediated scleritis need immune-suppressing treatment and close eye specialist follow-up.
Symptoms
A sore, deeply aching eye can make reading, driving, or looking at screens hard to get through. With immune-mediated scleritis, the discomfort is usually much stronger than the mild irritation people expect from dry eye or pink eye. Symptoms vary from person to person and can change over time. Some people have one affected eye, while others have repeat flares or symptoms in both eyes.
The pain is often severe, aching, or boring rather than scratchy, and it may spread to the brow, temple, jaw, or side of the face. It can be worse at night or when moving the eye, which may disturb sleep or make it hard to focus.
The eye often looks intensely red, sometimes with a darker pink or bluish tone rather than the bright surface redness of simple irritation. Many people with immune-mediated scleritis notice the redness does not improve much with routine eye drops.
Bright light can feel uncomfortable or painful, so being outdoors, driving in sunlight, or using screens may become difficult. Tearing and a tender, sore feeling in the eye often come with this.
Vision may become hazy, less sharp, or harder to focus during a flare. For some, changes in vision are among the early symptoms of immune-mediated scleritis and should be checked promptly.
How people usually first notice Immune-mediated scleritis?
Immune-mediated scleritis often first gets your attention as a deep, aching eye pain that can spread to the brow, jaw, or temple and feels much worse than ordinary eye irritation. Many people with immune-mediated scleritis also notice a striking red or violet-red eye, tenderness, light sensitivity, tearing, and sometimes blurred vision, and the pain may be severe enough to wake them from sleep or hurt more when they move the eye. Because the first signs of immune-mediated scleritis can look like “just a red eye” but may threaten vision, new severe eye pain with redness or any change in vision should be checked urgently by an eye specialist.
Types of Immune-mediated scleritis
Immune-mediated scleritis can affect day-to-day life in very different ways, from a deep, boring eye pain that makes it hard to sleep to blurred vision that turns reading or driving into a strain. Symptoms don’t always look the same for everyone. The main types of immune-mediated scleritis are based on which part of the white outer coat of the eye is inflamed and whether the inflammation is causing tissue damage. That is why the types of immune-mediated scleritis can differ in pain, redness, and the risk of vision problems.
Diffuse anterior
This is the most common type and usually causes deep eye pain, marked redness, tearing, and light sensitivity. The redness often spreads across a broad area of the white of the eye rather than forming one distinct spot. Vision may stay normal at first, but some people notice blur if the inflammation is more severe.
Nodular anterior
This type causes a tender, inflamed lump or raised area on the white of the eye along with the same deep aching pain seen in other forms. Many living with immune-mediated scleritis notice that the eye looks red in one more focused area rather than all over. The pain can still be intense, especially with eye movement or at night.
Necrotizing anterior
This is the most severe anterior form and can cause extreme pain, severe redness, and worsening vision as the eye tissue becomes damaged. The inflamed area may look darker, thinner, or patchy because the sclera is being injured. It needs urgent specialist care because it carries the highest risk of complications.
Scleromalacia perforans
This rare form is a necrotizing type with little or no pain and much less obvious redness, even though the sclera is thinning. It is seen most often in people with long-standing autoimmune disease, especially rheumatoid arthritis. Because symptoms can be subtle, changes may be noticed during an eye exam rather than from discomfort alone.
Posterior scleritis
This type affects the back part of the eye, so the outside of the eye may not look very red even when pain is significant. People may notice blurred vision, double vision, headache, or pain when moving the eye, and some may feel the symptoms are harder to pin down at first. It can sometimes mimic other eye problems, which makes prompt evaluation especially important.
Can I slow down the onset of symptoms?
Not really—there is no strong proof that lifestyle changes can meaningfully delay the start of immune-mediated scleritis, a painful inflammation of the white part of the eye. The clearest step that may help is keeping any related long-term inflammatory illness well controlled, and not smoking may also support overall health, but this may lower risk or reduce flares rather than prevent scleritis from happening. Regular follow-up with your doctor and an eye doctor, and getting urgent care for deep eye pain or redness, can protect vision and help problems be treated early, even though they cannot promise to delay symptoms.
What genetics can tell you about symptoms
For people with immune-mediated scleritis, genetics may help explain a higher tendency toward autoimmune inflammation, and certain immune-related gene patterns have been linked to overall risk, especially in those who also live with conditions like rheumatoid arthritis. Even so, genetic testing usually cannot tell which eye symptoms you will have, how painful or severe they will be, or exactly when they will start, because those details are shaped by several factors beyond genes. In practice, genetics can suggest background susceptibility more than it can predict the day-to-day pattern of symptoms.
Causes and risk factors
Immune-mediated scleritis often starts when the immune system mistakenly inflames the tough white layer of the eye. Many people with immune-mediated scleritis also have an autoimmune disease such as rheumatoid arthritis, lupus, vasculitis, or inflammatory bowel disease. It’s rarely just one factor—it’s the mix that matters. A family tendency toward autoimmune illness, being a middle-aged adult, and sometimes being female can raise risk. Smoking and other habits that worsen body-wide inflammation may add to the risk, so these are part of the causes of immune-mediated scleritis doctors consider.
What are the most common causes or risk factors?
Immune-mediated scleritis happens when the body’s defense system mistakenly attacks the white outer wall of the eye, and the biggest risk is having another illness where the immune system attacks healthy tissue. It is most often linked to conditions such as rheumatoid arthritis, lupus, bowel diseases that cause ongoing inflammation, or diseases that inflame blood vessels. It is also seen more often in women and in middle age, and a family tendency toward autoimmune disease may raise risk, although some people have no clear trigger.
Environmental and biological risk factors
Immune-mediated scleritis is most often linked to an overactive immune system rather than an infection or simple irritation. That said, biology and environment work hand in hand. In practice, the strongest risk factors for immune-mediated scleritis are body-wide inflammatory diseases, with a smaller role for outside triggers such as prior eye surgery, injury, or certain medicines.
Having an autoimmune condition is the clearest biological risk factor, especially rheumatoid arthritis. These conditions can misdirect the immune system toward the tough white wall of the eye and raise the chance of immune-mediated scleritis.
Diseases that inflame blood vessels, often grouped as vasculitis, are strongly linked to scleritis and can make it more severe. If immune-mediated scleritis appears along with inflammation in places such as the sinuses, lungs, skin, or kidneys, doctors often look for one of these disorders.
Lupus, Sjogren syndrome, and relapsing polychondritis can also increase risk. Sometimes the eye problem is what leads doctors to uncover one of these conditions.
Inflammatory bowel disease and inflammatory arthritis, including psoriasis-related arthritis and ankylosing spondylitis, are recognized risk factors. For some people, eye inflammation shows up when the underlying condition is active elsewhere in the body.
Genetic risk factors
Immune-mediated scleritis usually does not come from a single inherited gene. When people ask about the genetic risk factors for immune-mediated scleritis, the main pattern is an inherited tendency toward autoimmune disease and an overactive immune response. It is usually a combination of influences rather than one clear cause. This helps explain why some families have several immune-related conditions, while others have no clear history at all.
Polygenic risk: Most immune-mediated scleritis appears to involve many small genetic differences rather than one inherited mutation. Together, these differences may make the immune system more likely to attack the white outer coat of the eye.
HLA genes: Certain HLA genes, which help the body tell its own tissues from infections, are linked with higher risk of autoimmune inflammation. This may help explain why immune-mediated scleritis sometimes appears alongside other immune diseases.
Family history: Having close relatives with autoimmune disease can suggest a shared inherited tendency, even if no one else in the family has had scleritis. This is especially relevant when several family members have conditions driven by immune system overactivity.
Linked autoimmune diseases: Some of the strongest genetic clues come from diseases that often occur with immune-mediated scleritis, such as rheumatoid arthritis, lupus, inflammatory bowel disease, and some types of blood vessel inflammation. Genes tied to those conditions may also raise the chance of eye inflammation.
Lifestyle risk factors
Immune-mediated scleritis is driven mainly by abnormal inflammation, but daily habits can still influence how active symptoms become and how well the eye recovers during treatment. When people ask about lifestyle risk factors for immune-mediated scleritis, the strongest concerns are behaviors that increase systemic inflammation, delay treatment, or worsen irritation. Good lifestyle habits do not replace medical care, but they may help reduce avoidable flares and complications.
Smoking promotes inflammation and blood vessel damage, which can make scleral inflammation harder to control. It may also reduce healing and increase the risk of complications during active disease.
Skipping steroids, immunosuppressive drugs, or follow-up visits can allow inflammation to persist or return quickly. In immune-mediated scleritis, delayed control raises the risk of severe pain, scleral thinning, and vision-threatening damage.
Chronic sleep loss can increase inflammatory signaling and make pain feel worse. Poor sleep may also reduce resilience during flares and make it harder to manage complex treatment plans.
Ongoing psychological stress can amplify immune activity and worsen pain perception. For some people, stress may be one factor linked to more frequent or more severe inflammatory flare-ups.
Risk prevention
Immune-mediated scleritis often cannot be fully prevented, because it is driven by the immune system and is frequently linked to conditions such as rheumatoid arthritis or other inflammatory diseases. In practice, prevention usually means lowering the chance of a first episode or flare, protecting the eye, and treating related health problems early. Prevention is about lowering risk, not eliminating it completely.
The most important step is keeping any underlying autoimmune or inflammatory disease well managed. When body-wide inflammation is quieter, immune-mediated scleritis is less likely to start or flare again.
Regular follow-up with your eye doctor and, if needed, a rheumatologist can catch trouble before vision is affected. Small changes on an exam may appear before severe pain or other early symptoms of immune-mediated scleritis become obvious.
Taking prescribed anti-inflammatory or immune-calming treatment exactly as directed can lower the risk of repeat inflammation. Stopping steroid or immune treatment suddenly without medical advice can sometimes trigger a flare.
New deep eye pain, redness, light sensitivity, or pain that wakes you at night should be checked quickly. Fast treatment can reduce the risk of thinning of the eye wall and lasting vision problems.
Can you prevent Immune-mediated scleritis?
Immune-mediated scleritis cannot usually be fully prevented, because it happens when the body’s defense system mistakenly attacks the white outer part of the eye. For many living with it, the best way to lower the chance of flare-ups is to keep any related immune condition well controlled, take treatment as directed, and have regular follow-up with their doctor. Getting help early for new eye pain or redness can also stop inflammation from becoming more severe, even if it does not prevent it completely.
Transmission
Immune-mediated scleritis is not contagious, so it cannot be passed from one person to another through touching, coughing, sharing towels, or close contact. Many people wonder, is immune-mediated scleritis contagious, but this form of scleritis happens because the immune system triggers inflammation in the white outer coat of the eye, not because of a germ that spreads between people.
It is also not usually inherited in a simple, direct way from parent to child, although the autoimmune conditions linked to immune-mediated scleritis can sometimes run in families. In practical terms, people living with immune-mediated scleritis do not need to isolate from others because it is not considered infectious.
When to test your genes
For immune-mediated scleritis, genetic testing is not part of routine early detection or treatment planning. What matters more is a careful eye exam and evaluation for linked autoimmune conditions such as rheumatoid arthritis or vasculitis. Gene testing may be considered only in unusual cases, strong family history, or research settings.
Diagnosis
Immune-mediated scleritis is usually diagnosed after an eye specialist evaluates deep eye pain, redness, and vision changes, then looks for signs of inflammation in the white outer coat of the eye. It’s natural to worry when symptoms don’t have a clear explanation. The diagnosis of immune-mediated scleritis often also includes checking for related autoimmune or inflammatory conditions elsewhere in the body.
An ophthalmologist examines the eye with a slit lamp to see whether the deeper wall of the eye is inflamed rather than just the surface. This helps tell immune-mediated scleritis apart from more common causes of a red eye, such as conjunctivitis or episcleritis.
Doctors usually begin by asking about deep, boring eye pain, light sensitivity, tearing, blurred vision, and whether the pain wakes you at night or spreads to the face or jaw. These details can strongly support how immune-mediated scleritis is diagnosed and how urgent treatment may be.
A detailed family and health history can help uncover autoimmune diseases such as rheumatoid arthritis, lupus, inflammatory bowel disease, or vasculitis that may be linked to the eye inflammation. Doctors also ask about infections, injuries, and recent eye surgery because these can point to other causes.
Blood work may look for signs of inflammation and clues to an underlying immune condition, and other lab tests may help rule out common conditions that can mimic it. Depending on the situation, tests may also check for infection because treatment differs if germs rather than the immune system are driving the problem.
How is Immune-mediated scleritis diagnosed?
Immune-mediated scleritis is usually diagnosed by an eye doctor based on your symptoms, especially deep eye pain and redness, and a careful eye exam using a bright light and magnifying lenses. Blood tests may be done to look for signs of inflammation in the body and to check for related illnesses, and some people also need an eye ultrasound or scan if the deeper parts of the eye may be involved. There is no routine genetic test for this condition.
Stages of Immune-mediated scleritis
Immune-mediated scleritis does not have defined progression stages. That is because it is usually described by how severe the inflammation is, which part of the white of the eye is affected, and whether it comes in flares rather than moving through fixed step-by-step phases. Doctors usually start with a conversation about eye pain, redness, blurred vision, and other early symptoms of immune-mediated scleritis, then examine the eye closely and may arrange imaging or blood tests to look for related inflammatory conditions. Monitoring usually focuses on whether inflammation is active, whether vision is changing, and how well treatment is controlling symptoms.
Outlook and prognosis
The outlook for immune-mediated scleritis is often good when it is recognized early and treated promptly, but prognosis depends on whether the inflammation is mild and localized or severe, recurrent, and associated with an underlying systemic autoimmune disease. Many people achieve control of pain and inflammation with corticosteroids and steroid-sparing immunosuppressive therapy, though relapses are common and some patients require long-term treatment. Visual prognosis is usually favorable in anterior non-necrotizing disease, while necrotizing scleritis and posterior scleritis carry a much higher risk of permanent vision loss from complications such as scleral thinning, uveitis, glaucoma, cataract, retinal detachment, or optic nerve damage. Outcomes are generally worse when scleritis occurs with rheumatoid arthritis, granulomatosis with polyangiitis, or systemic vasculitis, because these disorders can drive more aggressive ocular disease and increase overall medical risk. Mortality from scleritis itself is uncommon, but survival can be affected by the underlying autoimmune or vasculitic condition, particularly if there is major organ involvement. Close follow-up with ophthalmology and, when needed, rheumatology improves both eye outcomes and overall prognosis.
Long-term effects
Immune-mediated scleritis can be more than a painful eye flare. When inflammation keeps coming back or is hard to control, it can damage the white outer coat of the eye and nearby tissues, sometimes leading to lasting vision problems. The long-term picture is often very different from one person to another, depending on how severe the inflammation is, how often it returns, and whether another autoimmune disease is also present. Thinking about the long-term effects helps explain why close follow-up matters even after symptoms settle.
Immune-mediated scleritis often follows a relapsing course, with periods of improvement followed by new episodes of eye pain, redness, and tenderness. Over time, repeated inflammation can increase the chance of lasting eye damage.
Ongoing inflammation can thin and weaken the white wall of the eye, a change doctors may call scleral thinning. In severe cases, the eye becomes more fragile and more vulnerable to shape changes or injury.
Some people with immune-mediated scleritis develop blurred vision that does not fully return to normal after severe or repeated inflammation. The long-term effects of immune-mediated scleritis are more likely to affect sight when deeper parts of the eye also become involved.
Inflammation may spread to nearby structures, including the cornea, retina, or the layer under the sclera, which can lead to scarring or fluid-related changes. For many, symptoms and vision changes depend as much on these complications as on the scleral inflammation itself.
How is it to live with Immune-mediated scleritis?
Living with immune-mediated scleritis can feel like your eye has become the center of the day: deep, aching pain, redness, light sensitivity, and blurred vision can make reading, screen time, driving, and even sleep much harder. Many people living with this condition also have to plan around flares, medical visits, and treatments that may affect energy or mood, so daily routines can become less predictable. For family, friends, and coworkers, the biggest impact is often practical and emotional support, because during painful periods you may need help with transportation, brighter environments can be difficult, and the worry about protecting vision can affect everyone close to you.
Treatment and drugs
Immune-mediated scleritis is usually treated by calming the inflammation quickly to protect the eye and relieve deep pain, redness, and light sensitivity. Treatment often starts with anti-inflammatory medicines, but many people with immune-mediated scleritis need stronger drugs that quiet the immune system, such as steroids and other immune-suppressing medicines, especially when symptoms are severe or keep coming back. If an infection has not been fully ruled out, doctors are careful before using these medicines because the wrong treatment can make an infection worse. Not every treatment works the same way for every person, so an eye specialist may change the drug or dose over time and may also work with a rheumatologist if there is an autoimmune disease elsewhere in the body. Alongside medical treatment, lifestyle choices play a role, such as taking medicines exactly as prescribed, going to follow-up visits, and getting urgent care if you notice worsening eye pain or changes in vision.
Can you cure Immune-mediated scleritis?
There is not usually a permanent cure for immune-mediated scleritis, but it can often be brought under control with treatment. Treatment focuses on calming the inflammation, easing pain, protecting vision, and treating any related immune condition, often with steroid medicines or other drugs that quiet an overactive immune system. Many people do well, although the problem can come back and may need ongoing care.
Non-drug treatment
Immune-mediated scleritis can make everyday tasks hard because the eye may feel deeply painful, light-sensitive, and tender, sometimes enough to make reading, driving, or screen time difficult. Alongside medicines, non-drug therapies often focus on protecting the eye, easing strain, and helping you manage the underlying autoimmune condition that can trigger flares. For many, treatment begins not at the pharmacy, but with practical steps like limiting bright light, using cool compresses, and keeping close follow-up with eye and rheumatology teams. These measures do not replace medical treatment, but they can support comfort and may help people respond quickly to worsening symptoms.
Regular visits with an eye specialist are a key part of care for immune-mediated scleritis. These appointments help track inflammation, look for damage to deeper eye layers, and catch early signs that vision could be at risk.
Many living with immune-mediated scleritis also have an autoimmune condition such as rheumatoid arthritis or lupus, so coordinated care matters. Working closely with rheumatology and primary care can help reduce flares and support overall health.
Dark sunglasses, avoiding wind, and taking breaks from bright screens can reduce light sensitivity and day-to-day discomfort. Some may find that simple changes in lighting at home or work make reading and computer use easier.
A cool, clean compress placed gently over the closed eye may soothe aching and tenderness for short periods. It should feel calming, not icy or heavy, since pressure on a painful eye can make symptoms worse.
Your genes may have an impact on how drugs work for you
For people living with immune-mediated scleritis, treatment often means medicines that calm pain and bring an overactive immune system under control, but the same medicine can work very well for one person and less well for another. Part of that difference may come from small inherited differences in how the body breaks down medicines like steroids or other immune-calming drugs, which can affect how much help they bring and how likely side effects are. This kind of gene-and-medicine matching is called pharmacogenomics, but for scleritis it is not yet a routine part of care for most people, so treatment is still usually guided by symptoms, eye exams, and how someone responds over time.
Pharmacological treatments
Immune-mediated scleritis often causes deep, boring eye pain that can make reading, driving, or even moving the eye hard to tolerate, so treatment usually aims to calm inflammation quickly and protect vision. The treatment for immune-mediated scleritis often starts with anti-inflammatory medicine, but many people also need stronger immune-calming drugs if symptoms are severe or keep coming back. Not everyone responds to the same medication in the same way. The exact choice depends on how active the scleritis is, whether one or both eyes are involved, and whether there is an autoimmune condition elsewhere in the body.
Nonsteroidal anti-inflammatory drugs such as indomethacin, ibuprofen, or naproxen are often used first for milder immune-mediated scleritis. They can reduce pain and inflammation, though they may not be enough for more severe disease.
Prednisone is commonly used when pain is intense, redness is marked, or the eye is at higher risk. These medicines can work quickly, but doctors usually try to taper them because long-term use can cause important side effects.
In selected cases, doctors may use steroid injections near the eye, such as triamcinolone, when inflammation is very localized. This approach is used carefully because it is not right for every type of scleritis.
Methotrexate is one of the most common steroid-sparing medicines for immune-mediated scleritis, and azathioprine or mycophenolate mofetil are also widely used. These drugs help control inflammation over time and can reduce the need for ongoing steroid treatment.
Genetic influences
When severe eye pain and redness interrupt reading, driving, or even sleep, many people living with immune-mediated scleritis wonder why it happens. It’s natural to ask whether immune-mediated scleritis runs in families. Genetics may influence immune-mediated scleritis indirectly, because some of the same immune system genes linked to autoimmune diseases can make this kind of eye inflammation more likely. Even so, immune-mediated scleritis is usually not caused by one single inherited gene change, and many people have no clear family pattern. For many, the stronger clue is a personal or family history of autoimmune conditions, such as rheumatoid arthritis, rather than scleritis itself. Genetic testing is not a routine part of care for immune-mediated scleritis, but doctors may think more about inherited risk when eye inflammation happens alongside other autoimmune symptoms or a strong family history.
Is Immune-mediated scleritis genetic?
Genetics can influence who is more likely to develop immune-mediated scleritis, but they are only part of the picture. Immune-related gene variations may raise risk, while infections, autoimmune disease, and other triggers also matter.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are common throughout the general population. Most of these variants do not directly affect health and simply reflect natural human diversity. For many genes, having a variant associated with a condition suggests a possible link rather than a certain diagnosis, especially when several genes and environmental factors are involved. In some situations, though, a single well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
If eye pain, redness, and light sensitivity from immune-mediated scleritis keep flaring, finding a treatment that settles the inflammation quickly becomes very important. Genes may affect both the immune signals driving the disease and how your body handles certain medicines, so two people with immune-mediated scleritis can respond differently to the same treatment. Not every difference in response is genetic, but doctors sometimes use genetic testing before azathioprine, an immune-calming medicine, because changes in TPMT or NUDT15 can raise the risk of serious side effects such as dangerously low blood counts. For steroids, methotrexate, mycophenolate, and biologic drugs, genetics may play some part, but treatment is still guided mostly by how severe the eye inflammation is, whether another autoimmune condition is present, and how you have responded in the past. If you are wondering whether genetic testing for immune-mediated scleritis treatment could help, it is usually most useful when a medicine has a known gene-related safety concern rather than as a routine test for everyone.
Interactions with other conditions
Eye pain, light sensitivity, and redness from immune-mediated scleritis can sometimes be part of a bigger health picture, especially when inflammation is also affecting joints, blood vessels, skin, or the bowel. Many living with immune-mediated scleritis also have an autoimmune disease such as rheumatoid arthritis, lupus, inflammatory bowel disease, or certain forms of vasculitis, so flare-ups in the eye may happen around the same time another condition becomes more active. Doctors call it a “comorbidity” when two conditions occur together. In some people, immune-mediated scleritis can also appear with infections or after eye surgery, which is one reason doctors look carefully for the cause before choosing treatment, since medicines that calm the immune system can worsen an untreated infection. Day to day, this can mean that early symptoms of immune-mediated scleritis should not be ignored, especially if someone already lives with an autoimmune condition or has new joint pain, rashes, mouth ulcers, or bowel symptoms. Because these overlaps can affect both diagnosis and treatment, people with immune-mediated scleritis often do best when eye specialists and other doctors coordinate care.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Immune-mediated scleritis?
A red, painful eye can also be caused by a milder inflammation in the surface layer over the white of the eye, called episcleritis, as well as pink eye, a scratch or infection of the clear front part of the eye, or inflammation deeper inside the eye, called uveitis. In some cases, sudden glaucoma, which is a fast rise in eye pressure, can look similar too, especially when there is severe pain, blurred vision, halos around lights, or nausea.
History
Long before doctors could look closely at the layers of the eye, people described bouts of deep eye pain, marked redness, and vision trouble that could make ordinary tasks hard. Reading, driving, or even stepping outside on a bright day could become difficult when the white of the eye was not just irritated, but inflamed more deeply. What we now call immune-mediated scleritis gradually came to be recognized as a distinct condition rather than a routine “red eye.”
Early medical writing often grouped many painful eye problems together, so immune-mediated scleritis was not clearly separated from infections or more surface-level inflammation at first. As medical science evolved, doctors learned that inflammation in the tough outer coat of the eye could behave differently from common conjunctivitis and often needed more urgent care. This helped explain why some people had severe, boring eye pain and tenderness that seemed out of proportion to how the eye looked at first glance.
By the 19th and 20th centuries, improvements in eye examination made it easier to tell apart the deeper forms of eye inflammation. Doctors also began noticing that some people with scleritis had other inflammatory illnesses elsewhere in the body, such as joint or blood vessel disease. That connection was important, because it shifted thinking away from simple irritation and toward an immune-driven process in at least many cases.
In recent decades, awareness has grown that immune-mediated scleritis can vary widely, from milder episodes to severe inflammation that threatens vision if treatment is delayed. Better imaging, more precise eye exams, and a broader understanding of immune disease have all improved diagnosis. Today, the history of immune-mediated scleritis helps explain why early symptoms of immune-mediated scleritis, especially deep pain, light sensitivity, and persistent redness, are taken seriously and usually assessed promptly by an eye specialist.